Skip to content
value.today

Vigilant Biosciences, Inc.

🇺🇸 Miami, Florida, USAHealth CareFounded 2011
Total raised
$27 M
4 rounds on record
Latest round
$17 M
May 2018
First round on record
Feb 2013
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Vigilant Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2018$17 MNo. 4$10 to $50 million

Vigilant Biosciences, Inc.: Raise no. 4, May 2018

Investors in this round

15 investors had bought by the notice of Nov 25, 2019: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$17 M of $17 M offered
Smallest investment taken
$26,633
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Robert Hamilton · Executive Officer
  • William Brodie · Executive Officer, Director
  • Linda Niessen · Director
  • Timothy Barabe · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total amount of the offering sold includes the conversion of convertible promissory notes.”

Signed by Robert Hamilton, Chief Financial Officer. Newest notice filed Nov 25, 2019 (1 amendment). Read the notice at the SEC.

equitySEC
Nov 2015$3 MNo. 3$2 to $10 million

Vigilant Biosciences, Inc.: Raise no. 3, Nov 2015

Investors in this round

15 investors had bought by the notice of Feb 9, 2016: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $5 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Matthew H.J. Kim · Executive Officer, Director
  • Robert T. Hamilton · Executive Officer
  • Eric M. Stone · Director
  • Linda C. Niessen · Director
  • Timothy C. Barabe · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Matthew H.J. Kim, Ceo. Newest notice filed Feb 9, 2016. Read the notice at the SEC.

equitySEC
Dec 2014$5 MNo. 2$2 to $10 million

Vigilant Biosciences, Inc.: Raise no. 2, Dec 2014

Investors in this round

18 investors had bought by the notice of Mar 12, 2015: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Matthew H. J. Kim · Executive Officer, Director
  • Eric H. J. Stone · Director
  • Timothy H. J. Barabe · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Matthew H.J. Kim, Ceo. Newest notice filed Mar 12, 2015. Read the notice at the SEC.

equitySEC
Feb 2013$2 MNo. 1$2 to $10 million

Vigilant Biosciences, Inc.: Raise no. 1, Feb 2013

Investors in this round

23 investors had bought by the notice of Mar 25, 2014: 23 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Matthew H. J. Kim · Executive Officer, Director
  • Eric H. J. Stone · Director
  • Jeffrey H. J. Goodman · Director
  • Jonathan T. Lord · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Matthew H. J. Kim, Chief Executive Officer. Newest notice filed Mar 25, 2014. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Vigilant Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2019).

    SEC Form D · Nov 2019

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Nov 2019

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Vigilant Biosciences, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Vigilant Biosciences, Inc.
NameRoleNamed in
Robert HamiltonExecutive officerNov 2019
William BrodieExecutive officerNov 2019
Stuart HeapExecutive officerJun 2018
Matthew H.J. KimExecutive officerFeb 2016
Robert T. HamiltonExecutive officerFeb 2016
Matthew H. J. KimExecutive officerMar 2015
Linda NiessenDirectorNov 2019
Timothy BarabeDirectorNov 2019
William BrodieDirectorNov 2019
Eric StoneDirectorJun 2018
Stuart HeapDirectorJun 2018
Eric M. StoneDirectorFeb 2016
Linda C. NiessenDirectorFeb 2016
Matthew H.J. KimDirectorFeb 2016
Timothy C. BarabeDirectorFeb 2016
Eric H. J. StoneDirectorMar 2015
Matthew H. J. KimDirectorMar 2015
Timothy H. J. BarabeDirectorMar 2015
Jeffrey H. J. GoodmanDirectorMar 2014
Jonathan T. LordDirectorMar 2014